

Table 1.88A Specific Hallucinogen, Inhalant, Needle, and Heroin Use in Lifetime, by Age Group: Numbers in Thousands, 2011 and 2012

Drug or Method of Administration	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
HALLUCINOGENS	36,362	37,908	930	823	6,029	6,103	29,403	30,982
PCP (Angel Dust, Phencyclidine)	6,103	6,552	76	96	351	345	5,676	6,112
LSD (Acid)	23,000	23,735	229	249	2,054	2,056	20,716	21,430
Peyote	5,257	5,925	45	48	283	316	4,929	5,561
Mescaline	7,840	7,891	23	28	376	336	7,440	7,527
Psilocybin (Mushrooms)	20,881	20,989	339	319	3,480	3,226	17,063	17,445
Ecstasy (MDMA)	14,570 ^b	16,162	605 ^a	488	4,222	4,452	9,743 ^b	11,222
INHALANTS	20,523	21,095	1,877 ^b	1,613	3,106	2,918	15,540	16,563
Amyl Nitrite, Poppers, Locker Room Odorizers, or Rush	7,017	6,729	304 ^a	228	590	498	6,124	6,002
Correction Fluid, Degreaser, or Cleaning Fluid	1,841	1,709	351	332	299	238	1,190	1,139
Gasoline or Lighter Fluid	3,295	3,375	579	535	443	455	2,272	2,385
Glue, Shoe Polish, or Toluene	3,347	3,118	648	582	401	378	2,298	2,158
Halothane, Ether, or Other Anesthetics	980	858	85 ^a	44	145	112	750	702
Lacquer Thinner or Other Paint Solvents	1,746	1,559	255	245	247	202	1,243	1,113
Lighter Gases (Butane, Propane)	734	771	170	156	115	100	449	515
Nitrous Oxide or Whippits	11,263	12,139	240	189	1,893	1,812	9,131 ^a	10,138
Spray Paints	2,087	1,755	634 ^a	532	351	301	1,102	922
Other Aerosol Sprays	2,145	2,113	397 ^a	321	610 ^a	494	1,138	1,299
NEEDLE USE^{1,2,3}	3,639	4,039	48	47	383	466	3,208	3,526
Heroin Needle Use ^{1,2}	1,846	2,079	21	21	224	292	1,602	1,767
Cocaine Needle Use ^{1,2}	1,957	2,027	10	6	135	154	1,812	1,867
Stimulant Needle Use ^{1,2,3}	1,619	1,821	26	16	165	160	1,427	1,646
Methamphetamine Needle Use ^{1,2,3}	1,345	1,589	21	11	107	130	1,217	1,448
HEROIN	4,162	4,565	70	59	594	664	3,499	3,841
Smoke Heroin ²	1,402	1,760	36	27	260	320	1,106	1,412
Sniff or Snort Heroin ²	2,964	3,276	37	18	400	467	2,527	2,790

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Refers to lifetime use of a needle to inject a drug that was not prescribed, or that was taken only for the experience or feeling it caused.

² These drug estimates are generated from data collected on a "noncore" module of the NSDUH questionnaire. Therefore, these estimates may be somewhat inconsistent with drug estimates based on data collected from the "core" modules because NSDUH data are not edited for consistency across the "core" and "noncore" modules of the interview.

³ Estimates of Stimulant Needle Use, Methamphetamine Needle Use, and the Needle Use summary variable include data from new methamphetamine items added in 2005 and 2006 and are not comparable with estimates presented in NSDUH reports prior to the 2007 National Findings report. See Section B.4.8 in Appendix B of the *Results from the 2008 National Survey on Drug Use and Health: National Findings*.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.88B Specific Hallucinogen, Inhalant, Needle, and Heroin Use in Lifetime, by Age Group: Percentages, 2011 and 2012

Drug or Method of Administration	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
HALLUCINOGENS	14.1	14.6	3.7	3.3	17.6	17.6	14.8	15.4
PCP (Angel Dust, Phencyclidine)	2.4	2.5	0.3	0.4	1.0	1.0	2.9	3.0
LSD (Acid)	8.9	9.1	0.9	1.0	6.0	5.9	10.4	10.7
Peyote	2.0	2.3	0.2	0.2	0.8	0.9	2.5	2.8
Mescaline	3.0	3.0	0.1	0.1	1.1	1.0	3.8	3.8
Psilocybin (Mushrooms)	8.1	8.1	1.4	1.3	10.1 ^a	9.3	8.6	8.7
Ecstasy (MDMA)	5.7 ^b	6.2	2.4 ^a	2.0	12.3	12.9	4.9 ^b	5.6
INHALANTS	8.0	8.1	7.5 ^b	6.5	9.1	8.4	7.8	8.3
Amyl Nitrite, Poppers, Locker Room Odorizers, or Rush	2.7	2.6	1.2 ^a	0.9	1.7	1.4	3.1	3.0
Correction Fluid, Degreaser, or Cleaning Fluid	0.7	0.7	1.4	1.3	0.9	0.7	0.6	0.6
Gasoline or Lighter Fluid	1.3	1.3	2.3	2.1	1.3	1.3	1.1	1.2
Glue, Shoe Polish, or Toluene	1.3	1.2	2.6	2.3	1.2	1.1	1.2	1.1
Halothane, Ether, or Other Anesthetics	0.4	0.3	0.3 ^a	0.2	0.4	0.3	0.4	0.4
Lacquer Thinner or Other Paint Solvents	0.7	0.6	1.0	1.0	0.7	0.6	0.6	0.6
Lighter Gases (Butane, Propane)	0.3	0.3	0.7	0.6	0.3	0.3	0.2	0.3
Nitrous Oxide or Whippits	4.4	4.7	1.0	0.8	5.5	5.2	4.6	5.1
Spray Paints	0.8	0.7	2.5 ^a	2.1	1.0	0.9	0.6	0.5
Other Aerosol Sprays	0.8	0.8	1.6 ^a	1.3	1.8 ^a	1.4	0.6	0.6
NEEDLE USE ^{1,2,3}	1.4	1.6	0.2	0.2	1.1	1.3	1.6	1.8
Heroin Needle Use ^{1,2}	0.7	0.8	0.1	0.1	0.7	0.8	0.8	0.9
Cocaine Needle Use ^{1,2}	0.8	0.8	0.0	0.0	0.4	0.4	0.9	0.9
Stimulant Needle Use ^{1,2,3}	0.6	0.7	0.1	0.1	0.5	0.5	0.7	0.8
Methamphetamine Needle Use ^{1,2,3}	0.5	0.6	0.1	0.0	0.3	0.4	0.6	0.7
HEROIN	1.6	1.8	0.3	0.2	1.7	1.9	1.8	1.9
Smoke Heroin ²	0.5	0.7	0.1	0.1	0.8	0.9	0.6	0.7
Sniff or Snort Heroin ²	1.2	1.3	0.1	0.1	1.2	1.4	1.3	1.4

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Refers to lifetime use of a needle to inject a drug that was not prescribed, or that was taken only for the experience or feeling it caused.

² These drug estimates are generated from data collected on a "noncore" module of the NSDUH questionnaire. Therefore, these estimates may be somewhat inconsistent with drug estimates based on data collected from the "core" modules because NSDUH data are not edited for consistency across the "core" and "noncore" modules of the interview.

³ Estimates of Stimulant Needle Use, Methamphetamine Needle Use, and the Needle Use summary variable include data from new methamphetamine items added in 2005 and 2006 and are not comparable with estimates presented in NSDUH reports prior to the 2007 National Findings report. See Section B.4.8 in Appendix B of the *Results from the 2008 National Survey on Drug Use and Health: National Findings*.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.89A Nonmedical Use of Specific Pain Relievers in Lifetime, by Age Group: Numbers in Thousands, 2011 and 2012

Pain Reliever	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Darvocet [®] , Darvon [®] , or Tylenol [®] with Codeine	16,507 ^a	18,079	900	837	2,767	2,808	12,840 ^b	14,435
Percocet [®] , Percodan [®] , or Tylox [®]	12,910 ^a	14,136	422	361	3,059	3,012	9,429 ^b	10,763
Vicodin [®] , Lortab [®] , or Lorcet [®]	21,262 ^b	23,731	948	850	5,511	5,548	14,803 ^b	17,332
Codeine	6,407	6,825	365	335	1,790	1,694	4,252	4,796
Demerol [®]	1,851	1,901	42	42	294	287	1,515	1,572
Dilaudid [®]	1,008 ^b	1,762	9	12	257	334	742 ^b	1,417
Fioricet [®]	441	359	21	9	49	58	370	291
Fiorinal [®]	224	249	25	16	32	32	167	200
Hydrocodone	9,779 ^b	11,416	451 ^a	371	2,884	3,034	6,444 ^b	8,011
Methadone	2,104	2,460	150 ^a	98	761	737	1,192 ^a	1,625
Morphine	2,696 ^b	3,587	188	179	963	1,098	1,546 ^b	2,310
OxyContin [®]	5,917 ^a	6,579	369	322	2,079	2,011	3,469 ^a	4,247
Phenaphen [®] with Codeine	599	625	52	48	170	157	377	420
Propoxyphene	255	269	17	29	54	60	183	180
SK-65 [®]	25	42	7	15	18	18	*	*
Stadol [®]	102	105	3	5	2	17	97	84
Talacen [®]	57	50	8	12	7	11	42	26
Talwin [®]	192	232	10	17	*	22	180	193
Talwin [®] NX	55	122	12	4	5	15	39	102
Tramadol	2,165 ^b	2,719	144 ^b	87	712 ^a	857	1,309 ^a	1,775
Ultram [®]	1,155	1,299	32	32	263	234	860	1,033
SELECTED GROUPS OF DRUGS¹								
Propoxyphene or Codeine Products ²	18,465 ^a	20,058	1,066	1,014	3,481	3,463	13,917 ^b	15,581
Oxycodone Products ³	14,817 ^a	16,027	643	562	3,777	3,678	10,397 ^b	11,788
Hydrocodone Products ⁴	23,226 ^b	25,675	1,114	1,014	6,037	6,086	16,075 ^b	18,575
Tramadol Products ⁵	2,614 ^b	3,233	159 ^b	101	794	914	1,660 ^b	2,218

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Includes other-specify drug responses that are not asked about explicitly in the Pain Relievers module but fall into this category.

² Includes Darvocet[®], Darvon[®] or Tylenol[®] with Codeine, codeine, Phenaphen[®] with Codeine, propoxyphene, and SK-65[®].

³ Includes Percocet[®], Percodan[®] or Tylox[®], and OxyContin[®].

⁴ Includes Vicodin[®], Lortab[®], or Lorcet[®], and hydrocodone.

⁵ Includes tramadol and Ultram[®].

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.89B Nonmedical Use of Specific Pain Relievers in Lifetime, by Age Group: Percentages, 2011 and 2012

Pain Reliever	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Darvocet [®] , Darvon [®] , or Tylenol [®] with Codeine	6.4 ^a	7.0	3.6	3.4	8.1	8.1	6.5 ^a	7.2
Percocet [®] , Percodan [®] , or Tylox [®]	5.0 ^a	5.4	1.7	1.4	8.9	8.7	4.8 ^a	5.4
Vicodin [®] , Lortab [®] , or Lorcet [®]	8.3 ^b	9.1	3.8	3.4	16.1	16.0	7.5 ^b	8.6
Codeine	2.5	2.6	1.5	1.3	5.2	4.9	2.1	2.4
Demerol [®]	0.7	0.7	0.2	0.2	0.9	0.8	0.8	0.8
Dilaudid [®]	0.4 ^b	0.7	0.0	0.0	0.7	1.0	0.4 ^b	0.7
Fioricet [®]	0.2	0.1	0.1	0.0	0.1	0.2	0.2	0.1
Fiorinal [®]	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Hydrocodone	3.8 ^b	4.4	1.8 ^a	1.5	8.4	8.8	3.2 ^b	4.0
Methadone	0.8	0.9	0.6 ^a	0.4	2.2	2.1	0.6 ^a	0.8
Morphine	1.0 ^b	1.4	0.8	0.7	2.8	3.2	0.8 ^b	1.2
OxyContin [®]	2.3	2.5	1.5	1.3	6.1	5.8	1.7 ^a	2.1
Phenaphen [®] with Codeine	0.2	0.2	0.2	0.2	0.5	0.5	0.2	0.2
Propoxyphene	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1
SK-65 [®]	0.0	0.0	0.0	0.1	0.1	0.1	*	*
Stadol [®]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Talacen [®]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Talwin [®]	0.1	0.1	0.0	0.1	*	0.1	0.1	0.1
Talwin [®] NX	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
Tramadol	0.8 ^a	1.0	0.6 ^b	0.4	2.1 ^a	2.5	0.7 ^a	0.9
Ultram [®]	0.4	0.5	0.1	0.1	0.8	0.7	0.4	0.5
SELECTED GROUPS OF DRUGS¹								
Propoxyphene or Codeine Products ²	7.2 ^a	7.7	4.3	4.1	10.1	10.0	7.0 ^a	7.8
Oxycodone Products ³	5.8	6.2	2.6	2.3	11.0	10.6	5.2 ^a	5.9
Hydrocodone Products ⁴	9.0 ^b	9.9	4.5	4.1	17.6	17.6	8.1 ^b	9.3
Tramadol Products ⁵	1.0 ^b	1.2	0.6 ^b	0.4	2.3	2.6	0.8 ^a	1.1

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Includes other-specify drug responses that are not asked about explicitly in the Pain Relievers module but fall into this category.

² Includes Darvocet[®], Darvon[®] or Tylenol[®] with Codeine, codeine, Phenaphen[®] with Codeine, propoxyphene, and SK-65[®].

³ Includes Percocet[®], Percodan[®] or Tylox[®], and OxyContin[®].

⁴ Includes Vicodin[®], Lortab[®], or Lorcet[®], and hydrocodone.

⁵ Includes tramadol and Ultram[®].

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.90A Nonmedical Use of Specific Tranquilizers in Lifetime, by Age Group: Numbers in Thousands, 2011 and 2012

Tranquilizer	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Klonopin® or Clonazepam	5,094 ^a	5,799	191	184	1,433	1,598	3,470	4,017
Xanax®, Alprazolam, Ativan®, or Lorazepam	13,657 ^b	15,613	513	517	3,494	3,687	9,650 ^b	11,410
Valium® or Diazepam	12,649	13,045	210	221	1,750	1,745	10,690	11,079
Atarax®	128	236	10	13	30	53	88	170
BuSpar®	694	732	25	20	196	167	474	545
Equanil®	67	55	3	7	4	18	60	30
Flexeril®	2,454 ^b	3,149	59	36	563	528	1,832 ^b	2,585
Librium®	499	695	8	12	49	57	442	626
Limbitrol®	54	62	6	11	10	21	37	31
Meprobamate	79	133	21	13	20	27	37	93
Miltown®	38 ^a	161	7	7	5	24	26	130
Rohypnol®	290	256	22	27	64	69	204	160
Serax®	50	53	3	7	19	25	28	21
Soma®	3,062 ^a	3,690	83	63	894	820	2,086 ^b	2,808
Tranxene®	140	113	5	5	23	18	112	90
Vistaril®	254	263	19	13	51	74	184	176
SELECTED GROUPS OF DRUGS¹								
Benzodiazepines ²	20,409 ^a	22,086	644	655	3,990	4,249	15,776 ^a	17,182
Meprobamate Products ³	168	268	26	20	26	45	116	203
Muscle Relaxants ⁴	4,623 ^b	5,530	115	85	1,188	1,119	3,320 ^b	4,326

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Includes other-specify drug responses that are not asked about explicitly in the Tranquilizers module but fall into this category.

² Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan® or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®.

³ Includes Equanil®, meprobamate, and Miltown®.

⁴ Includes Flexeril® and Soma®.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.90B Nonmedical Use of Specific Tranquilizers in Lifetime, by Age Group: Percentages, 2011 and 2012

Tranquilizer	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Klonopin® or Clonazepam	2.0 ^a	2.2	0.8	0.7	4.2	4.6	1.7	2.0
Xanax®, Alprazolam, Ativan®, or Lorazepam	5.3 ^b	6.0	2.1	2.1	10.2	10.7	4.9 ^b	5.7
Valium® or Diazepam	4.9	5.0	0.8	0.9	5.1	5.0	5.4	5.5
Atarax®	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.1
BuSpar®	0.3	0.3	0.1	0.1	0.6	0.5	0.2	0.3
Equanil®	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
Flexeril®	1.0 ^b	1.2	0.2	0.1	1.6	1.5	0.9 ^b	1.3
Librium®	0.2	0.3	0.0	0.0	0.1	0.2	0.2	0.3
Limbitrol®	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0
Meprobamate	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.0
Miltown®	0.0 ^a	0.1	0.0	0.0	0.0	0.1	0.0	0.1
Rohypnol®	0.1	0.1	0.1	0.1	0.2	0.2	0.1	0.1
Serax®	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0
Soma®	1.2 ^a	1.4	0.3	0.3	2.6	2.4	1.1 ^b	1.4
Tranxene®	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.0
Vistaril®	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1
SELECTED GROUPS OF DRUGS¹								
Benzodiazepines ²	7.9 ^a	8.5	2.6	2.6	11.6	12.3	8.0	8.6
Meprobamate Products ³	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Muscle Relaxants ⁴	1.8 ^b	2.1	0.5	0.3	3.5	3.2	1.7 ^b	2.2

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Includes other-specify drug responses that are not asked about explicitly in the Tranquilizers module but fall into this category.

² Includes Klonopin® or clonazepam, Xanax®, alprazolam, Ativan® or lorazepam, Valium® or diazepam, Librium®, Limbitrol®, Rohypnol®, Serax®, and Tranxene®.

³ Includes Equanil®, meprobamate, and Miltown®.

⁴ Includes Flexeril® and Soma®.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.91A Nonmedical Use of Specific Stimulants in Lifetime, by Age Group: Numbers in Thousands, 2011 and 2012

Stimulant	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Methamphetamine, Desoxyn [®] , or Methedrine ¹	11,928	12,259	184	145	1,150	1,089	10,594	11,025
Prescription Diet Pills ²	6,586	7,246	112	125	582 ^a	729	5,892	6,391
Ritalin [®] or Methylphenidate	4,918 ^b	6,008	245	242	1,687	1,790	2,986 ^b	3,976
Cylert [®]	126	112	8	8	34	22	84	82
Dexedrine [®]	1,898	1,689	10	14	100	100	1,788	1,575
Dextroamphetamine	734	770	29	18	164	193	541	558
Didrex [®]	133	97	5	3	21	9	107	85
Eskatrol [®]	40	148	5	6	6	14	28	128
Ionamin [®]	335	300	3	4	12	3	319	294
Mazanor [®]	47	38	3	10	7	11	37	17
Obedrin-LA [®]	*	20	7	5	*	*	*	14
Plegine [®]	17	26	*	5	4	6	13	15
Preludin [®]	301	335	3	6	21	19	276	310
Sanorex [®]	79	40	4	14	14	6	60	20
Tenuate [®]	156	100	6	2	7	10	143	88
SELECTED GROUPS OF DRUGS³								
Amphetamine, Dextroamphetamine, and Phentermine Products ⁴	8,784	9,400	200	232	1,302 ^a	1,519	7,283	7,650
Mazindol Products ⁵	114	74	7 ^a	22	18	15	88	37
Methylphenidate or Dexmethylphenidate Products ⁶	4,931 ^b	6,050	252	245	1,693	1,816	2,986 ^b	3,990

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Also known as crank, crystal, ice, or speed. Estimates of Use of Methamphetamine, Desoxyn[®], or Methedrine include data from new methamphetamine items added in 2005 and 2006 and are not comparable with estimates presented in NSDUH reports prior to the 2007 National Findings report. See Section B.4.8 in Appendix B of the *Results from the 2008 National Survey on Drug Use and Health: National Findings*.

² Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine[®], Biphentamine[®], Fastin[®], or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills.

³ Includes other-specify drug responses that are not asked about explicitly in the Stimulants module but fall into this category.

⁴ Includes prescription diet pills, Dexedrine[®], dextroamphetamine, and Ionamin[®].

⁵ Includes Mazanor[®] and Sanorex[®].

⁶ Includes Ritalin[®], other products containing methylphenidate, and products containing dexmethylphenidate.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.91B Nonmedical Use of Specific Stimulants in Lifetime, by Age Group: Percentages, 2011 and 2012

Stimulant	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Methamphetamine, Desoxyn [®] , or Methedrine ¹	4.6	4.7	0.7	0.6	3.4	3.1	5.3	5.5
Prescription Diet Pills ²	2.6	2.8	0.4	0.5	1.7 ^a	2.1	3.0	3.2
Ritalin [®] or Methylphenidate	1.9 ^b	2.3	1.0	1.0	4.9	5.2	1.5 ^b	2.0
Cylert [®]	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0
Dexedrine [®]	0.7	0.6	0.0	0.1	0.3	0.3	0.9	0.8
Dextroamphetamine	0.3	0.3	0.1	0.1	0.5	0.6	0.3	0.3
Didrex [®]	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0
Eskatrol [®]	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1
Ionamin [®]	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.1
Mazanor [®]	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Obedrin-LA [®]	*	0.0	0.0	0.0	*	*	*	0.0
Plegine [®]	0.0	0.0	*	0.0	0.0	0.0	0.0	0.0
Preludin [®]	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.2
Sanorex [®]	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
Tenuate [®]	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0
SELECTED GROUPS OF DRUGS³								
Amphetamine, Dextroamphetamine, and Phentermine Products ⁴	3.4	3.6	0.8	0.9	3.8 ^a	4.4	3.7	3.8
Mazindol Products ⁵	0.0	0.0	0.0 ^a	0.1	0.1	0.0	0.0	0.0
Methylphenidate or Dexmethylphenidate Products ⁶	1.9 ^b	2.3	1.0	1.0	4.9	5.2	1.5 ^b	2.0

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Also known as crank, crystal, ice, or speed. Estimates of Use of Methamphetamine, Desoxyn[®], or Methedrine include data from new methamphetamine items added in 2005 and 2006 and are not comparable with estimates presented in NSDUH reports prior to the 2007 National Findings report. See Section B.4.8 in Appendix B of the *Results from the 2008 National Survey on Drug Use and Health: National Findings*.

² Respondents were asked about their use of prescription diet pills and were given the following as examples: amphetamines, Benzedrine[®], Biphentamine[®], Fastin[®], or phentermine. However, respondents were not given an exhaustive list of examples of prescription diet pills.

³ Includes other-specify drug responses that are not asked about explicitly in the Stimulants module but fall into this category.

⁴ Includes prescription diet pills, Dexedrine[®], dextroamphetamine, and Ionamin[®].

⁵ Includes Mazanor[®] and Sanorex[®].

⁶ Includes Ritalin[®], other products containing methylphenidate, and products containing dexmethylphenidate.

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.92A Nonmedical Use of Specific Sedatives in Lifetime, by Age Group: Numbers in Thousands, 2011 and 2012

Sedative	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Methaqualone, Sopor [®] , or Quaalude [®]	5,217	5,159	17	24	96 ^a	56	5,104	5,079
Barbiturates ¹	2,055	2,069	22	24	41	37	1,993	2,008
Restoril [®] or Temazepam	811 ^a	1,246	32 ^a	58	115	140	664	1,047
Amytal [®]	251 ^a	120	7	10	17	10	226	100
Butisol [®]	72	164	8	6	20	16	45	142
Chloral Hydrate	122	92	5	7	4	14	113	72
Dalmane [®]	340 ^a	164	5	9	6	19	329 ^a	136
Halcion [®]	327	435	14	10	17	22	296	404
Phenobarbital	755	835	17	22	29	30	709	784
Placidyl [®]	526	660	2	4	*	5	524	651
Tuinal [®]	696	724	2	3	*	9	693	712
SELECTED GROUPS OF DRUGS²								
Temazepam, Flurazepam, or Triazolam ³	1,261	1,686	48	69	129	161	1,085	1,455
Any Barbiturates ⁴	2,569	2,627	46	58	87	78	2,435	2,491

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal[®], pentobarbital, Seconal[®], secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates.

² Includes other-specify drug responses that are not asked about explicitly in the Sedatives module but fall into this category.

³ Includes Restoril[®], temazepam, Dalmane[®], or Halcion[®].

⁴ Includes barbiturates, Amytal[®], Butisol[®], phenobarbital, and Tuinal[®].

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.

Table 1.92B Nonmedical Use of Specific Sedatives in Lifetime, by Age Group: Percentages, 2011 and 2012

Sedative	Total (2011)	Total (2012)	Aged 12-17 (2011)	Aged 12-17 (2012)	Aged 18-25 (2011)	Aged 18-25 (2012)	Aged 26+ (2011)	Aged 26+ (2012)
Methaqualone, Sopor [®] , or Quaalude [®]	2.0	2.0	0.1	0.1	0.3 ^a	0.2	2.6	2.5
Barbiturates ¹	0.8	0.8	0.1	0.1	0.1	0.1	1.0	1.0
Restoril [®] or Temazepam	0.3 ^a	0.5	0.1 ^a	0.2	0.3	0.4	0.3	0.5
Amytal [®]	0.1 ^a	0.0	0.0	0.0	0.1	0.0	0.1 ^a	0.1
Butisol [®]	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1
Chloral Hydrate	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0
Dalmane [®]	0.1 ^a	0.1	0.0	0.0	0.0	0.1	0.2 ^a	0.1
Halcion [®]	0.1	0.2	0.1	0.0	0.0	0.1	0.1	0.2
Phenobarbital	0.3	0.3	0.1	0.1	0.1	0.1	0.4	0.4
Placidyl [®]	0.2	0.3	0.0	0.0	*	0.0	0.3	0.3
Tuinal [®]	0.3	0.3	0.0	0.0	*	0.0	0.3	0.4
SELECTED GROUPS OF DRUGS²								
Temazepam, Flurazepam, or Triazolam ³	0.5	0.6	0.2	0.3	0.4	0.5	0.5	0.7
Any Barbiturates ⁴	1.0	1.0	0.2	0.2	0.3	0.2	1.2	1.2

*Low precision; no estimate reported.

^a Difference between estimate and 2012 estimate is statistically significant at the 0.05 level.

^b Difference between estimate and 2012 estimate is statistically significant at the 0.01 level.

¹ Respondents were asked about their use of barbiturates and were given the following as examples: Nembutal[®], pentobarbital, Seconal[®], secobarbital, or butalbital. However, respondents were not given an exhaustive list of examples of barbiturates.

² Includes other-specify drug responses that are not asked about explicitly in the Sedatives module but fall into this category.

³ Includes Restoril[®], temazepam, Dalmane[®], or Halcion[®].

⁴ Includes barbiturates, Amytal[®], Butisol[®], phenobarbital, and Tuinal[®].

Source: SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2011 and 2012.